Impaired cardiac function has been related to accelerated cognitive decline in late-life.
Objective:
To investigate whether higher levels of high sensitivity cardiac troponin T (hs-cTnT), a sensitive marker for myocardial injury, are associated with worse cognitive function in the oldest old.
Methods:
In 455 participants of the population-based Leiden 85-plus Study, hs-cTnT was measured at 86 years. Cognitive function was measured annually during four years with the Mini-Mental State Examination (MMSE).
Results:
Participants in the highest gender-specific tertile of hs-cTnT had a 2.0-point lower baseline MMSE score than participants in the lowest tertile (95% confidence interval (CI) (95% CI 0.73–3.3), and had a 0.58-point steeper annual decline in MMSE during follow-up (95% CI 0.06–1.1). The associations remained after adjusting for sociodemographic and cardiovascular risk factors excluding those without a history of overt cardiac disease.
Conclusion:
In a population-based sample of the oldest old, higher levels of hs-cTnT were associated with worse cognitive function and faster cognitive decline, independently from cardiovascular risk factors and a history of overt cardiac disease.
AdamsJE3rd, AbendscheinDR, JaffeAS (1993) Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s?Circulation88, 750–763.
NagarajanV, HernandezAV, TangWH (2012) Prognostic value of cardiac troponin in chronic stable heart failure: A systematic review. Heart98, 1778–1786.
4.
JanuzziJLJr, FilippatosG, NieminenM, GheorghiadeM (2012) Troponin elevation in patients with heart failure: On behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J33, 2265–2271.
5.
FredaBJ, TangWH, Van LenteF, PeacockWF, FrancisGS (2002) Cardiac troponins in renal insufficiency: Review and clinical implications. J Am Coll Cardiol40, 2065–2071.
6.
BecattiniC, VedovatiMC, AgnelliG (2007) Prognostic value of troponins in acute pulmonary embolism: A meta-analysis. Circulation116, 427–433.
7.
SaundersJT, NambiV, de LemosJA, ChamblessLE, ViraniSS, BoerwinkleE, HoogeveenRC, LiuX, AstorBC, MosleyTH, FolsomAR, HeissG, CoreshJ, BallantyneCM (2011) Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation123, 1367–1376.
8.
WallaceTW, AbdullahSM, DraznerMH, DasSR, KheraA, McGuireDK, WiansF, SabatineMS, MorrowDA, de LemosJA (2006) Prevalence and determinants of troponin T elevation in the general population. Circulation113, 1958–1965.
9.
DanielsLB, LaughlinGA, CloptonP, MaiselAS, Barrett-ConnorE (2008) Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: Results from the Rancho Bernardo Study. J Am Coll Cardiol52, 450–459.
10.
EverettBM, BrooksMM, VlachosHE, ChaitmanBR, FryeRL, BhattDL, GroupBDS (2015) Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med373, 610–620.
11.
FolsomAR, NambiV, BellEJ, OluleyeOW, GottesmanRF, LutseyPL, HuxleyRR, BallantyneCM (2013) Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: The atherosclerosis risk in communities study. Stroke44, 961–967.
12.
HijaziZ, OldgrenJ, AnderssonU, ConnollySJ, EzekowitzMD, HohnloserSH, ReillyPA, VinereanuD, SiegbahnA, YusufS, WallentinL (2012) Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: A Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation125, 1605–1616.
13.
QiuC, FratiglioniL (2015) A major role for cardiovascular burden in age-related cognitive decline. Nat Rev Cardiol12, 267–277.
14.
RusanenM, KivipeltoM, LevalahtiE, LaatikainenT, TuomilehtoJ, SoininenH, NganduT (2014) Heart diseases and long-term risk of dementia and Alzheimer’s disease: A population-based CAIDE study. J Alzheimers Dis42, 183–191.
15.
FeinkohlI, KellerM, RobertsonCM, MorlingJR, WilliamsonRM, NeeLD, McLachlanS, SattarN, WelshP, ReynoldsRM, RussTC, DearyIJ, StrachanMW, PriceJF, Edinburgh Type 2 Diabetes Study I (2013) Clinical and subclinical macrovascular disease as predictors of cognitive decline in older patients with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Diabetes Care36, 2779–2786.
16.
AbeteP, Della-MorteD, GargiuloG, BasileC, LangellottoA, GaliziaG, TestaG, VincenzoC, BonaduceD, CacciatoreF (2014) Cognitive impairment and cardiovascular diseases in the elderly. A heart-brain continuum hypothesis. Ageing Res Rev18, 41–52.
17.
Van der WielAB, van ExelE, de CraenAJ, GusseklooJ, LagaayAM, KnookDL, WestendorpRG (2002) A high response is not essential to prevent selection bias: Results from the Leiden 85-plus study. J Clin Epidemiol55, 1119–1125.
18.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
19.
MooijaartSP, van VlietP, van HeemstD, RensenPC, BerbeeJF, JollesJ, de CraenAJ, WestendorpRG (2007) Plasma levels of apolipoprotein E and cognitive function in old age. Ann N Y Acad Sci1100, 148–161.
20.
ConnorsMH, SachdevPS, KochanNA, XuJ, DraperB, BrodatyH (2015) Cognition and mortality in older people: The Sydney Memory and Ageing Study. Age Ageing44, 1049–1054.
21.
SchneiderAL, RawlingsAM, SharrettAR, AlonsoA, MosleyTH, HoogeveenRC, BallantyneCM, GottesmanRF, SelvinE (2014) High-sensitivity cardiac troponin T and cognitive function and dementia risk: The atherosclerosis risk in communities study. Eur Heart J35, 1817–1824.
22.
WijsmanLW, de CraenAJ, TrompetS, SabayanB, MullerM, StottDJ, FordI, WelshP, WestendorpRG, JukemaJW, SattarN, MooijaartSP (2016) High-sensitivity cardiac troponin T is associated with cognitive decline in older adults at high cardiovascular risk. Eur J Prev Cardiol23, 1383–1392.
23.
HilalS, ChaiYL, IkramMK, ElangovanS, YeowTB, XinX, ChongJY, VenketasubramanianN, RichardsAM, ChongJP, LaiMK, ChenC (2015) Markers of cardiac dysfunction in cognitive impairment and dementia. Medicine (Baltimore)94, e297.
24.
PoortvlietRK, BlomJW, de CraenAJ, MooijaartSP, WestendorpRG, AssendelftWJ, GusseklooJ, de RuijterW (2013) Low blood pressure predicts increased mortality in very old age even without heart failure: The Leiden 85-plus Study. Eur J Heart Fail15, 528–533.
25.
Weverling-RijnsburgerAW, BlauwGJ, LagaayAM, KnookDL, MeindersAE, WestendorpRG (1997) Total cholesterol and risk of mortality in the oldest old. Lancet350, 1119–1123.
26.
PetersenLK, ChristensenK, KragstrupJ (2010) Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age Ageing39, 674–680.
27.
TakashioS, YamamuroM, IzumiyaY, SugiyamaS, KojimaS, YamamotoE, TsujitaK, TanakaT, TayamaS, KaikitaK, HokimotoS, OgawaH (2013) Coronary microvascular dysfunction and diastolic load correlate with cardiac troponin T release measured by a highly sensitive assay in patients with nonischemic heart failure. J Am Coll Cardiol62, 632–640.
28.
SabayanB, van BuchemMA, SigurdssonS, ZhangQ, HarrisTB, GudnasonV, AraiAE, LaunerLJ (2015) Cardiac Hemodynamics are Linked With Structural and Functional Features of Brain Aging: The Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study. J Am Heart Assoc4, e001294.
29.
DaduRT, FornageM, ViraniSS, NambiV, HoogeveenRC, BoerwinkleE, AlonsoA, GottesmanRF, MosleyTH, BallantyneCM (2013) Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study. Stroke44, 1803–1808.
30.
GorelickPB, ScuteriA, BlackSE, DeCarliC, GreenbergSM, IadecolaC, LaunerLJ, LaurentS, LopezOL, NyenhuisD, PetersenRC, SchneiderJA, TzourioC, ArnettDK, BennettDA, ChuiHC, HigashidaRT, LindquistR, NilssonPM, RomanGC, SellkeFW, SeshadriS (2011) Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke42, 2672–2713.
31.
van der VelpenIF, FeleusS, BertensAS, SabayanB (2017) Hemodynamic and serum cardiac markers and risk of cognitive impairment and dementia. Alzheimers Dement13, 441–453.
32.
CushmanM, CallasPW, McClureLA, UnverzagtFW, HowardVJ, GillettSR, ThackerEL, WadleyVG (2016) N-terminal pro-B-type natriuretic peptide and risk of future cognitive impairment in the REGARDS Cohort. J Alzheimers Dis54, 497–503.
33.
KaraK, MahabadiAA, WeimarC, WinklerA, NeumannT, KalschH, DraganoN, MoebusS, ErbelR, JockelKH, JokischM (2017) N-terminal pro-B type natriuretic peptide is associated with mild cognitive impairment in the general population. J Alzheimers Dis55, 359–369.
34.
HumpelC (2011) Identifying and validating biomarkers for Alzheimer’s disease. Trends Biotechnol29, 26–32.
35.
O’BryantSE, GuptaV, HenriksenK, EdwardsM, JerominA, ListaS, BazenetC, SoaresH, LovestoneS, HampelH, MontineT, BlennowK, ForoudT, CarrilloM, Graff-RadfordN, LaskeC, BretelerM, ShawL, TrojanowskiJQ, SchupfN, RissmanRA, FaganAM, OberoiP, UmekR, WeinerMW, GrammasP, PosnerH, MartinsR, STAR-B and BBBIG working groups (2015) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement11, 549–560.
